. 2019 Jan 10;21(2):321–329. doi: 10.1111/dom.13607

Table 3.

Univariable and multivariable analyses using potential prognostic and explanatory factors to estimate the probability of reaching HbA1c less than 7.0% (<53 mmol/mol) at Week 24 in participants with type 2 diabetes

Variable	Categorical or continuous	Odds ratio (95% CI)	P value
Univariable analysis
Age at baseline	Per 10 y	1.02 (0.95, 1.10)	0.513
Sex	Women vs men	0.76 (0.66, 0.87)	<0.0001
Body weight at baseline	≥83.0 vs <83.0 kg	1.38 (1.20, 1.58)	<0.0001
Body weight at baseline	Continuous (per 10 kg)^a	1.09 (1.05, 1.13)	<0.0001
BMI at baseline	≥30.0 vs <30.0 kg/m²	1.21 (1.06, 1.38)	0.006
BMI at baseline	Continuous (per 5 kg/m²)	1.09 (1.02, 1.16)	0.008
Diabetes duration	≥10 vs <10 y	0.61 (0.53, 0.70)	<0.0001
Diabetes duration	Continuous (per year)^a	0.96 (0.95, 0.97)	<0.0001
HbA1c at baseline	≥8.5 vs <8.5%^b	0.35 (0.30, 0.40)	<0.0001
	Continuous (per 1 mmol/mol)^a	0.94 (0.94, 0.95)	<0.0001
	Continuous (per 1%‐unit)^a	0.53 (0.50, 0.58)	<0.0001
FPG at baseline	≥11.1 vs <11.1 mmol/L^c	0.59 (0.51, 0.68)	<0.0001
	Continuous (per 1 mmol/L)^a	0.91 (0.89, 0.93)	<0.0001
	Continuous (per 10 mg/dL)^a	1.00 (0.99, 1.00)	<0.0001
2‐h SMPG at baseline (all meals)	≥11.7 vs <11.7 mmol/L^d	0.48 (0.41, 0.56)	<0.0001
	Continuous (per 1 mmol/L)^a	0.86 (0.84, 0.89)	<0.0001
	Continuous (per 10 mg/dL)^a	0.99 (0.99, 0.99)	<0.0001
Baseline fasting C‐peptide	≥1.2 vs <1.2 nmol/L	1.00 (0.84, 1.20)	0.97
Baseline fasting C‐peptide	Continuous (per 0.2 nmol/L)^a	1.00 (1.00, 1.00)	0.28
Sulfonylurea use during study	Yes vs no	0.61 (0.52, 0.71)	<0.0001
Hypoglycaemia^a during study	No vs yes	0.65 (0.57, 0.75)	<0.0001
Change in FPG	Continuous (per 10 mg/dL)	0.99 (0.98, 1.00)	0.19 0.19
Change in FPG	Continuous (per 1 mmol/L)^a	0.99 (0.97, 1.01)	0.19 0.19
Change in 2‐h SMPG (all meals)	Continuous (per 10 mg/dL)	1.00 (0.99, 1.01)	0.76 0.76
Change in 2‐h SMPG (all meals)	Continuous (per 1 mmol/L)^a	1.00 (0.97, 1.02)	0.76 0.76
Change in body weight	Continuous (per 1.0 kg)	0.92 (0.90, 0.94)	<0.0001
Final Gla‐100 dose	Continuous (per 0.1 U/kg)	0.93 (0.91, 0.96)	<0.0001
Multivariable analysis model using categorical and continuous variables
Sex	Women vs men	0.76 (0.64, 0.91)	0.0021
Diabetes duration	≥10 vs <10 y	0.63 (0.53, 0.75)	<0.0001
HbA1c at baseline	≥8.5 vs <8.5%^b	0.38 (0.32, 0.45)	<0.0001
2‐h SMPG at baseline (all meals)	≥11.7 vs <11.7 mmol/L^d	0.73 (0.61, 0.87)	0.0005
Body weight at baseline	≥83.0 vs <83.0 kg	1.29 (1.09, 1.54)	0.0034
Sulfonylurea use during study	Yes vs no	0.59 (0.49, 0.71)	<0.0001
Change in body weight	Continuous (per 1.0 kg)	0.94 (0.91, 0.96)	<0.0001
Hypoglycaemia^a during study	No vs yes	0.62 (0.53, 0.74)	<0.0001
Multivariable analysis model using continuous variables
Sex	Women vs men	0.70 (0.60, 0.83)	<0.0001
Diabetes duration	Per year	0.96 (0.95, 0.98)	<0.0001
HbA1c at baseline	Per 1 mmol/mol	0.94 (0.94, 0.95)	<0.0001
HbA1c at baseline	Per 1%‐unit	0.53 (0.48, 0.60)	<0.0001
FPG at baseline	Per 1 mmol/L	1.06 (1.02, 1.11)	0.003
FPG at baseline	Per 1 mg/dL	1.00 (1.00, 1.01)	0.0023
2‐h SMPG at baseline (all meals)	Per 1 mmol/L	0.93 (0.90, 0.96)	<0.0001
2‐h SMPG at baseline (all meals)	Per 1 mg/dL	1.00 (0.99, 1.00)	0.0005
BMI at baseline	Per 5.0 kg/m²	1.19 (1.08, 1.31)	0.0003
Change in body weight	Per 1.0 kg	0.94 (0.92, 0.97)	<0.0001
Hypoglycaemia^a during study	No vs yes	0.64 (0.54, 0.76)	<0.0001

Abbreviations: BMI, body mass index; CI, confidence interval; FPG, fasting plasma glucose; Gla‐100, glargine 100 U/mL; HbA1c, glycated haemoglobin A1c; PG, plasma glucose; SMPG, self‐monitored plasma glucose.

For multivariable analysis, n = 2626 patients were included. Outcomes of univariable and multivariable analysis using standardized predictors are shown in Table S2.

Confirmed with PG <3.9 mmol/L or severe hypoglycaemia.

≥69 vs <69 mmol/mol.

≥200 vs <200 mg/dL.

≥210 vs <210 mg/dL.